2-Amyl-benzamid | 100368-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Amyl-benzamid
• 英文别名: Amyl-Benzamid；2-pentylbenzamide
• CAS: 100368-67-0
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: XYBMEDCRQLHBNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Amyl-benzamid 在 盐酸 作用下， 生成 2-pentylbenzoic acid
  参考文献：
  名称：

  A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site

  摘要：

  The availability of peptide and non-peptide Ang II receptor antagonists has permitted the study of Ang II receptor heterogeneity. It is now widely recognized that there are at least two distinct Ang II receptor subtypes. AT(1) receptors are selective in their recognition of agents such as losartan, DuP 532, L-158,809, SK&F108566, and similar non-peptides. To date, all of the well-known actions of Ang II in mammals are blocked by the AT(1) selective antagonists such as losartan and are thus designated as being mediated by the AT(1) receptor. Although there have been reports of functional activity mediated through AT(2) sites, the pharmacological role for the AT(2) receptor has not yet been elucidated. Herein, we report the chemistry and SAR on a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids which have selective affinity for AT(2) receptors. The most potent of which (19) has an IC50 Of 30 nM for the AT(2) receptor in the rat adrenal radioligand binding assay.

  DOI：

  10.1021/jm00077a001
• 作为产物：
  描述：

  2-pentylbenzoic acid 生成 2-Amyl-benzamid
  参考文献：
  名称：

  Huisgen,R.; Rauenbusch,E., Justus Liebigs Annalen der Chemie, 1961, vol. 641, p. 51 - 62

  摘要：

  DOI：

文献信息

• [EN] PHENETHANOLAMINE DERIVATIVES<br/>[FR] DERIVES DE LA PHENETHANOLAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003091204A1

  公开（公告）日：2003-11-06

  The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物，或其盐、溶剂合物或生理功能衍生物，以及其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• [EN] CANNABINOID DERIVATIVES<br/>[FR] DÉRIVÉS DE CANNABINOÏDES
  申请人：CANOPY GROWTH CORP

  公开号：WO2021102568A1

  公开（公告）日：2021-06-03

  This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2 is methyl, R3 is CsHn, R4 is -C(O)N(R4a)(R4b), R5 is H, R6 is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.

  本公开涉及具有结构式(I)的大麻素衍生物，包括它们的药物组合物以及使用大麻素衍生物的方法。在某些实施例中，R1为- CH2CH=C(CH3)2，R2为甲基，R3为CsHn，R4为-C(O)N(R4a)(R4b)，R5为H，R6为OH，R7为H。本公开的化合物在CB1和CB2受体上以激动剂和拮抗剂模式进行了测试。通常发现被测试的化合物在CB1和CB2受体上表现出拮抗剂模式的活性。
• [EN] "INHIBITORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, COMPOSITIONS, PRODUCTS AND USES THEREOF"<br/>[FR] "INHIBITEURS DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE, COMPOSITIONS, PRODUITS ET LEURS UTILISATIONS"
  申请人：UNIVERSIT DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO

  公开号：WO2014178001A1

  公开（公告）日：2014-11-06

  Compounds of formula (I): able to inhibit nicotinamide phosphoribosyltransferase. The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which NAMPT inhibition might be beneficial, such as acute and chronic inflammation, cancer and metabolic disorders.

  化学式（I）的化合物：能够抑制烟酰胺磷酸核糖转移酶。该公开还涉及使用化学式（I）的化合物来治疗可能受益于NAMPT抑制的病理条件，如急性和慢性炎症、癌症和代谢紊乱。
• [EN] NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS [1.1.1] BICYCLO UTILISÉS COMME INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019204180A1

  公开（公告）日：2019-10-24

  Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文披露了一种化合物(I)的结构，它们是IDO酶的抑制剂：(I)。本文还披露了这些化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还披露了包含这些化合物的组合物。进一步披露了这些组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。
• BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS
  申请人：Keith John M.

  公开号：US20080004258A1

  公开（公告）日：2008-01-03

  Certain substituted butyl and butynyl benzyl amine compounds are histamine H 3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H 3 receptor- and/or serotonin-mediated diseases.

  某些取代的丁基和丁炔基苄胺化合物是组织胺H3受体和/或血清素转运蛋白调节剂，在治疗组织胺H3受体和/或血清素介导的疾病中具有用处。